China Law & Practice

Follow us:

profile

China Law & Practice

CLP_editorial

CLP_editorial profile

AmCham warns of China protectionism (again): http://t.co/w5mSgad9LV but banks pushing for a BIT: http://t.co/w5mSgad9LV

Feb 12 2015 04:02 ·  reply ·  retweet ·  favourite
CLP_editorial profile

RT @denisfberger: Shanghai IP court head Judge Wu on establishment of technical department and technical investigators - http://t.co/lZORwG…

Feb 12 2015 03:59 ·  reply ·  retweet ·  favourite
CLP_editorial profile

Ai-Leen Lim leaves @twobirds to join @Awapatent as CEO of their new Asia offices in BJ and HK: http://t.co/KOw2IRC7oZ

Feb 10 2015 02:53 ·  reply ·  retweet ·  favourite

Change font size: Switch to default font size Switch to medium font size Switch to large font size

Patent System to Catch Up with Pharmaceutical Industry Expansion

The pharmaceutical industry in China has been expanding in recent years as the government strives to invent its own drugs and brands. However, the prevalence of counterfeit and generic drugs still remains a significant IP issue. The patent system needs further development before it will be able to properly protect patent holders.

Keywords (click to search): Pharmaceutical drugs counterfeit generic

  The execution of Zheng Xiaoyu for corruption and dereliction of duty made headlines last year. As former director of Chinese watchdog the State Food and Drug Administration (SFDA), Zheng’s death sentence reflects the PRC government’s determination to protect consumers. For the pharmaceutical industry, the execution represented a step in the right direction. This sector has been widely criticized due to the prevalence of fake drugs and the lack of intellectual property (IP) protection from the government. The 2003 SARS attack, worldwide anger over deaths caused by the exportation of contaminated food and fake drugs, and Zheng’s approval of unsafe drugs in violation of new rules all exposed China’s lack of enforcement in the health care system. The Zheng scandal alerted the government to the need to reform the nation’s pharmaceutical image by promulgating new measures and regulations. At the opening of the National People’s Congress Premier Wen Jiabao emphasized the...


Register with China Law & Practice to unlock our premium content for the next 14 days.

**Full text translations are only available for individual purchase or as part of a subscription.
**